|Table of Contents|

Adrenocortical carcinoma：2 cases report and brief review of the literature

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2020 02
Page:
256-259
Research Field:
Publishing date:

Info

Title:
Adrenocortical carcinoma：2 cases report and brief review of the literature
Author(s):
Li Jiaxing; Yin Bo
Department of Urology,Shengjing Hospital of China Medical University,Liaoning Shenyang 110004,China.
Keywords:
adrenocortical carcinoma; mitotane; diagnosis; treatment
PACS:
R737.1
DOI:
10.3969/j.issn.1672-4992.2020.02.018
Abstract:
Objective:To discuss the clinical features of adrenocortical carcinoma（ACC）,so as to guide the clinical diagnosis and treatment of ACC.Methods:Analyze retrospectively the clinical data of two cases that the patients with ACC,and retrieve CNKI,Wan Fang,Pubmed and other databases,to systematically analyse the relevant literature and induce its clinical characteristics.Results:In this group,1 patient underwent open surgery for adrenal masse,underwent radiotherapy one month after surgery,and underwent bone scan,which indicated multiple bone metastasis,and was treated with anti-bone metastasis.Reexamination 5 months after surgery suggested multiple perirenalmetastasis.Oral antitumor therapy with mitotane,the patient died 2 years after surgery.1 patient underwent with laparoscopic adrenal mass resection,and postoperative pathology suggested hepatic metastasis.About three months after surgery,reexamination was performed.Hepatic area was occupied.Hepatic metastasis was considered,and oral anti-tumor therapy with mitotane was performed.Follow-up was conducted for 5 months,and no further progress was found.Conclusion:ACC is a rare urological tumor.Some don' t even have specific clinical manifestations.The diagnosis of ACC should be combined with clinical manifestations,adrenal endocrine examination,such as androgen and cortisol,and imaging data.The gold standard depends on pathology.Surgical resection should be the first choice for treatment.Adjuvant chemotherapy,radiotherapy,immunotherapy,targeted therapy and other treatments are feasible for the ACC that is difficult to be resected.

References:

［1］ Erickson LA，Rivera M，Zhang J.Adrenocortical carcinoma：Review and update［J］.Adv Anat Pathol，2014，21（3）：151-159.
［2］ Crowley MJ，Scognamiglio T，Liu YF，et al.Prostatespecificmembrane antigen is a potential anti-angiogenic target in adrenocortical carcinoma［J］.J Clin Endocrinol Metabol，2016，101(3):981-987.
［3］ Kerkhofs TM，Verhoeven ＲH，Vander Zwan JM，et al．Adrenocortical carcinoma:A population based study on incidence and survivalin the Netherlands since 1993［J］ ．Eur J Cancer，2013，49(11):2579-2586.
［4］ Else T，Kim AC，Sabolch A，et al．Adrenocortical carcinoma［J］．Endocr Rev，2014，35(2)：282-326．
［5］ LUO BF,ZENG FQ,LIANG ZL,et al.Adrenocortical carcinoma(report of 9 cases)［J］.J Clin Urol,2011,26(3):211-214.［罗兵锋，曾甫清，梁铸林，等.肾上腺皮质癌9例报告［J］.临床泌尿外科杂志，2011，26（3）：211-214.］
［6］ Turgeon C，Shen WT，Clark OH，et al．Risk assessment in 457 adrenal cortical carcinomas：How much doestumor size predict the likelihood of malignancy［J］?J Am CollSurg，2006，202(3)：423-430．
［7］ JIANG W,ZHU Y.Progress of diagnosis of adrenocortical carcinoma［J］.J Contemp Urol Reprod Oncol,2018,10(3):185-188.［蒋文，祝宇.肾上腺皮质癌的诊断进展［J］.现代泌尿生殖肿瘤杂志，2018，10（3）：185-188.］
［8］ CAI D,LI HZ,ZHANG YS.Progress of diagnosis and treatment of adrenocortical carcinoma［J］.Natl Med J China,2016,96(16):1307-1309.［蔡赕，李汉忠，张玉石.肾上腺皮质癌的诊治进展［J］.中华医学杂志,2016,96（16）:1307-1309.］
［9］ Xiao XR，Ye LY，Shi LX，et al．Diagnosis and treatment of adrenal tumors：A review of 35 year's experience［J］.Br J Urol，1998(82)：199-205．
［10］ Giordano TJ.Adrenocortical tumors:An integrated clinical,phathologic,and molecular approach at the University of Michigan［J］.Arch Pathol Lab Med,2010(134):1440-1443.
［11］ Luton JP，Cerdas S，Billaud L，et aI．Clinical features of adrenocortical carcinoma，prognostic factors，and the effect of mitotane therapy［J］．N Engl J Med，1990，322(17)：1195-1201.
［12］ Przytulska J，Rogala N，Bednarek-Tupikowska G．Currentand emerging therapies for adrenocortical carcinomareview［J］．Adv Clin Exp Med，2015，24(2)：185-193．
［13］ Crucitti F，Bellantone R，Ferrante A，et al．The Italian registry for adrenal cortical carcinoma：Analysis of amulti-institutional series of 129 patients［J］．Surgery，1996(119)：161-170．
［14］ WANG CP,GAO J,ZHANG J,et al.The clinicopathological characteristics of adrenal cortical carcinoma and adenoma and the expression and significance of epidermal growth factor receptor and vascular endothelial growth factor［J］.Chin J Pathol,2012,41(10):686-690.［王翠萍，高静，张洁，等．肾上腺皮质癌、腺瘤临床病理特征分析和表皮生长因子受体、血管内皮生长因子的表达及意义［J］.中华病理学杂志,2012,41（10）:686-690.］
［15］ Beuschlein F，weigel J，Saegerw，et al．Major prognostic role of Ki67 in locajized adrenocortical carcinoma after complete resection［J］．J Clin Endocrinol Metab，2015，100(3)：841-849．
［16］ Libe R，Borge I，Ronchi CL，et al．Prognostic factors in stageⅢ-Ⅳadrenocortical carcinomas(Acc)：An European Networkforthe study of Adrenal Tumor(ENSAT)study［J］．Ann Oncol，2015，26(10)：2119-2125．
［17］ Henry JF，Peix JL，Kraimps JL.Positional statement of the European Society of Endocrine Surgeons（ESES） on malignantadrenal tumors［J］.Langenbecks Arch Surg，2012，397（2）：145-146.
［18］ Berruti A，Baudin E，Gelderblom H，et al.Adrenalcancer：ESMO clinical practice guidelines for diagnosis，treatmentand follow-up［J］.Ann Oncol， 2012，23（7）：vii131-138.
［19］ LIAN JP,ZHU Y.Progress of treatment of adrenocortical carcinoma［J］.Journal of Modern Urology,2015,20(4):275-280.［廉建坡，祝宇.肾上腺皮质癌的治疗进展［J］.现代泌尿外科杂志，2015，20（4）：275-280.］
［20］ Zheng GY，Li HZ，Deng JH，et al.Open adrenalectomy versus laparoscopic adrenalectomy for adrenocortical carcinoma：A retrospective comparative study on short-term oncologic prognosis［J］.Onco Targets Ther，2018（11）：1625-1632.
［21］ Baudin E．Adrenocortical carcinoma［J］．Endocrinol Metab Clin North Am，2015，44(2)：411-434.
［22］ Fossa A，Rosok BI，Kazaryan AM，et al.Laparoscopic versusopen surgery in stage Ⅰ-Ⅲ adrenocortical carcinoma-a retrospective comparison of 32 patients［J］.Acta Oncol，2013，52（8）：1771-1777.
［23］ DU WL,CHEN Y,XIAO YS.Adrenocortical carcinoma with iliac bone metastasis(one case report)［J］.Chin J Urol,2016,37(9):712-713.［杜文亮，陈跃，肖永双.肾上腺皮质腺癌伴髂骨转移一例报告［J］.中华泌尿外科杂志，2016,37（9）：712-713.］
［24］ Datta J,Roses RE.Surgical management of adrenocortical carcinoma:An evidence-based approach［J］.Surg Oncol Clin Nam,2016（25）:153-170.
［25］ Sabolch A，Feng M，Griffith K，et al．Adjuvant and definitiveradiotherapy for adrenocortical carcinoma［J］．Int J Radiat Oncol Biol Phys，2011，80(5)：1477-1484．
［26］ YUE XY,WANG HY,LAI YX.Progress of treatment of adrenocortical carcinoma［J］.Shandong Medical Journal,2018,58(32):111-114.［岳晓妍，王浩宇，赖亚新.肾上腺皮质癌治疗方式研究进展［J］.山东医药，2018,58（32）：111-114.］

Memo

Memo:
National Natural Science Foundation of China（No.81372725）;国家自然科学基金资助项目（编号：81372725）;辽宁省重点研发计划攻关项目资助（编号：2017225038）
Last Update: 2019-11-29